[Adjuvant chemotherapy and/or hormone therapy after radical prostatectomy for high-risk prostate cancer]. / Chimiothérapie et/ou hormonothérapie adjuvantes après prostatectomie radicale des cancers de prostate à haut risque.

Cancer prostate is heterogeneous and may require a risk-adjusted approach to therapy. Improved survival rates are reported for adjuvant chemotherapy alone or in combination with hormone therapy. A specific gene expression signature can be used to identify and predict response to adjuvant standard hormone therapy or hormone therapy and chemotherapy after radical prostatectomy.